Overall verdict
Buy
7.5/10
1-year performance
-53.95%
Score breakdown
Down 54.0% over 1 year, 5% of the 52-week range.
Strongest: Growth 9.7/10. Weakest: Valuation 5.3/10.
14 analysts, target +1.7% vs the price.
Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States. It delivers customized healthcare experience to meet the needs of seniors through its Medicare Advantage plans. Alignment Healthcare, Inc. was founded in 2013 and is based in Orange, California.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nasdaq
United States
CEO
John Kao
Founded
2013
Employees
1 849
Revenue / employee
2.1M USD
Next earnings
October 29, 2026 (estimated)
Institutional holders
- BlackRock, Inc.9.75%
- WELLINGTON MANAGEMENT GROUP LLP9.46%
- FMR LLC7.02%
- T. Rowe Price Investment Management, Inc.6.61%
- VANGUARD PORTFOLIO MANAGEMENT LLC5.88%
- Invesco Ltd.5.22%
- BANK OF AMERICA CORP /DE/4.71%
- VANGUARD CAPITAL MANAGEMENT LLC4.10%
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC3.91%
- Other institutions57.90%
323 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
25.12 USD
52-week low
7.37 USD
1-year performance
-53.95%
Declining
Year-to-date performance
-60.20%
Declining
Drawdown
-67.30%
Major drawdown
Position in the 52-week range
5% of range
Range: 19.94 USD - 28.00 USD (2 methods agree)
The price implies growth of -5.33% per year; the company grows at 25.00%.
Net margin 0.9%, ROIC 7.6%, ROE 20.0%.
Net margin
0.89%
Low
Sector 1.67%|S&P 12.97%
Gross margin
—
Return on equity (ROE)
20.04%
Exceptional
Sector 8.69%|S&P 16.52%
Return on invested capital (ROIC)
7.63%
Exceptional
Free cash flow margin (FCF)
3.88%
Fair
Profit-to-cash conversion (FCF conversion)
4.36x
Exceptional
Margin stability
5.1 pts
Uneven
Revenue to net income
Growth
9.7/10Revenue up 31.6% over 1 year, 32.7% a year over 5.
Revenue (trailing 12 months)
4.6Md USD
Revenue growth (1y)
31.55%
Hyper-growth
Revenue growth (3y)
175.33%
Hyper-growth
EPS growth (1y)
127.27%
Hyper-growth
EPS CAGR (5y)
—
EPS revisions (3 months)
4.21%
Revised up
Valuation
5.3/10P/E 44.0x, forward P/E 45.3x, EV/EBITDA 14.6x, PEG 0.35.
P/E (TTM)
44.0x
Expensive
Sector 26.2x|S&P 23.0x
Forward P/E
45.3x
Very expensive
EV / EBITDA
14.6x
Fair
Sector 15.4x|S&P 14.5x
PEG
0.35
Growth unpriced
Sector 0.23|S&P 0.86
Fair value (reverse DCF)
23.21 USD
Deeply undervalued
Market cap
1.6Md USD
Financial strength
8.6/10Cash covers 209.8% of the debt, net debt/EBITDA -4.3x.
Net debt / EBITDA
-4.3x
Net cash
Gearing (net debt / equity)
-137.70%
Net cash
Cash
693M USD
Cash / market cap
42.53%
Very solid
Cash / total debt
209.82%
Net cash
Interest coverage
3.4x
Tight
Net debt
-365M USD
Equity
265M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 7.67 USD
- MM2011.38
- MM5014.08
- MM20018.36
- RSI 1414.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.34%
200-day average slope, 3 months
-2.44%
50-day average slope, 1 month
-23.78%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
5.35 % per day
Volatility change
+14.98%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 0.18 (10) | 0.49 (4) | 5 215 (12) | 156 (11) | 39 (8) |
| 2027 | 0.42 (9) | 0.75 (4) | 6 494 (12) | 222 (10) | 94 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 18, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALHC | 7.5 | 7.5 | 1.6Md USD | 44.0x | 0.9 % | 31.6 % | 7.6 % | -4.3x | 10.9 % | -54.0 % | ||
| 2 | SAUD3 | 7.5 | 6.6 | 8.0Md USD | 14.3x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.6 % | 5.3 % | ||
| 3 | UNH | 7.2 | 6.4 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 4 | HQY | 7.1 | 6.7 | 7.5Md USD | 32.6x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.7 % | ||
| 5 | ELV | 6.6 | 5.7 | 86.4Md USD | 17.7x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 22.7 % | ||
| 6 | CNC | 5.9 | 4.8 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 89.2 % | ||
| 7 | HUM | 5.6 | 4.3 | 45.0Md USD | 35.5x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 47.6 % | ||
| 8 | CLOV | 4.8 | 3.8 | 2.4Md USD | Not meaningful (loss) | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 38.3 % | ||
| 9 | MOH | 4.4 | 2.5 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % |
